A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Efgartigimod alfa (Primary) ; Prednisone
- Indications Pemphigus; Pemphigus vulgaris
- Focus Registrational; Therapeutic Use
- Acronyms ADDRESS
- Sponsors argenx
Most Recent Events
- 20 Dec 2023 Primary endpoint has not been met. (Proportion of Pemphigus Vulgaris (PV) participants who achieve complete clinical remission (CR) on minimal Prednisone therapy)
- 20 Dec 2023 Results presented in an argenx Media Release.
- 31 Oct 2023 According to Argenx media release, the topline data from this trial is expected around year-end 2023.